Interactions of Cisplatin and Daunorubicin at the chromatin level [PDF]
, 2020 Unexpectedly, the widely used anticancer agents Cisplatin (Cis-Pt) and Daunorubicin (Dauno) exhibited cell type- and concentration-dependent synergy or antagonism in vitro.
Bacsó, Zsolt +7 more
core +2 more sources
Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin [PDF]
, 2018 Objective: Deterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection.
Abrar, Mohammed Burhan +8 more
core +1 more source
Epirubicin. A new entry in the list of fetal cardiotoxic drugs? Intrauterine death of one fetus in a twin pregnancy. Case report and review of literature [PDF]
, 2015 BACKGROUND: Current knowledge indicate that epirubicin administration in late pregnancy is almost devoid of any fetal cardiotoxicity. We report a twin pregnancy complicated by breast cancer in which epirubicin administration was causatively linked to ...
BRUNELLI, Roberto +10 more
core +2 more sources
Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production [PDF]
, 2018 The ErbB2 blocker trastuzumab improves survival in oncologic patients, but can cause cardiotoxicity. The late Na+ current inhibitor ranolazine has been shown to counter experimental HF, including doxorubicin cardiotoxicity (a condition characterized by ...
Carlo G. Tocchetti +16 more
core +3 more sources
Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. [PDF]
, 2017 BackgroundTopoisomerase I (TOPO1) and topoisomerase IIα (TOP2A) are specific targets of multiple chemotherapy drugs. Increased expression of TOPO1 protein and amplification of the TOP2A gene have been associated with treatment response in colorectal and ...
Arguello, David +4 more
core +1 more source
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper [PDF]
, 2016 Objectives: In this paper, we present a review of critical concepts and research perspectives and produce recommendations on the optimal use of pixantrone in non-Hodgkin lymphoma (NHL) by group discussion from an expert panel appointed by the Italian ...
Barosi, Giovanni +7 more
core +1 more source
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. [PDF]
, 2016 BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies.
Cortes, Javier +10 more
core +2 more sources
Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC) [PDF]
, 2005 Background: The aim of this retrospective analysis was to evaluate the impact of trastuzumab-based regimens on the survival of patients with HER2-overexpressing metastatic breast cancer (MBC).
Baselga J +9 more
core +1 more source
Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer [PDF]
, 2007 Background: Patients with metastatic breast cancer (MBC) are increasingly exposed to anthracyclines and taxanes either during treatment of primary breast cancer or during initial therapy of metastatic disease.
Fasching, P. A. +13 more
core +1 more source